Search

Your search keyword '"Steuer, A. E."' showing total 532 results
Start Over Author "Steuer, A. E." Publication Year Range Last 10 years
532 results on '"Steuer, A. E."'

4. Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial

Author

Saba, Nabil F., Steuer, Conor E., Ekpenyong, Asari, McCook-Veal, Ashley, Magliocca, Kelly, Patel, Mihir, Schmitt, Nicole C., Stokes, William, Bates, James E., Rudra, Soumon, Remick, Jill, McDonald, Mark, Abousaud, Marin, Tan, Aik Choon, Fadlullah, Muhammad Zaki Hidayatullah, Chaudhary, Ritu, Muzaffar, Jameel, Kirtane, Kedar, Liu, Yuan, Chen, Georgia Z., Shin, Dong M., Teng, Yong, and Chung, Christine H.

Published
2024
Full Text
View/download PDF

9. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung CancerHER3-DXd in EGFR TKI–Resistant EGFR-Mutated NSCLC

Author

Jänne, Pasi A, Baik, Christina, Su, Wu-Chou, Johnson, Melissa L, Hayashi, Hidetoshi, Nishio, Makoto, Kim, Dong-Wan, Koczywas, Marianna, Gold, Kathryn A, Steuer, Conor E, Murakami, Haruyasu, Yang, James Chih-Hsin, Kim, Sang-We, Vigliotti, Michele, Shi, Rong, Qi, Zhenhao, Qiu, Yang, Zhao, Lihui, Sternberg, David, Yu, Channing, and Yu, Helena A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Lung, Lung Cancer, Clinical Research, Development of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Camptothecin, Carcinoma, Non-Small-Cell Lung, Disease-Free Survival, Dose-Response Relationship, Drug, ErbB Receptors, Female, Humans, Infusions, Intravenous, Lung Neoplasms, Male, Middle Aged, Neoplasm Metastasis, Treatment Outcome, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an antibody-drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. This phase I, dose escalation/expansion study included patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) with prior EGFR tyrosine kinase inhibitor (TKI) therapy. Among 57 patients receiving HER3-DXd 5.6 mg/kg intravenously once every 3 weeks, the confirmed objective response rate by blinded independent central review (Response Evaluation Criteria in Solid Tumors v1.1) was 39% [95% confidence interval (CI), 26.0-52.4], and median progression-free survival was 8.2 (95% CI, 4.4-8.3) months. Responses were observed in patients with known and unknown EGFR TKI resistance mechanisms. Clinical activity was observed across a broad range of HER3 membrane expression. The most common grade ≥3 treatment-emergent adverse events were hematologic toxicities. HER3-DXd has clinical activity in EGFR TKI-resistant cancers independent of resistance mechanisms, providing an approach to treat a broad range of drug-resistant cancers. SIGNIFICANCE: In metastatic EGFR-mutated NSCLC, after disease progression on EGFR TKI therapy, treatment approaches include genotype-directed therapy targeting a known resistance mechanism or chemotherapy. HER3-DXd demonstrated clinical activity spanning known and unknown EGFR TKI resistance mechanisms. HER3-DXd could present a future treatment option agnostic to the EGFR TKI resistance mechanism.See related commentary by Lim et al., p. 16.This article is highlighted in the In This Issue feature, p. 1.

Published
2022

11. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial

Author

Saba, Nabil F., Steuer, Conor E., Ekpenyong, Asari, McCook-Veal, Ashley, Magliocca, Kelly, Patel, Mihir, Schmitt, Nicole C., Stokes, William, Bates, James E., Rudra, Soumon, Remick, Jill, McDonald, Mark, Abousaud, Marin, Tan, Aik Choon, Fadlullah, Muhammad Zaki Hidayatullah, Chaudhary, Ritu, Muzaffar, Jameel, Kirtane, Kedar, Liu, Yuan, Chen, Georgia Z., Shin, Dong M., Teng, Yong, and Chung, Christine H.

Published
2023
Full Text
View/download PDF

19. Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma

Author

Saba, Nabil F., primary, Wong, Stuart J., additional, Nasti, Tahseen, additional, McCook-Veal, Ashley Alesia, additional, McDonald, Mark W., additional, Stokes, William A., additional, Anderson, Allyson M., additional, Ekpenyong, Asari, additional, Rupji, Manali, additional, Abousaud, Marin, additional, Rudra, Soumon, additional, Bates, James E., additional, Remick, Jill S., additional, Joshi, Nikhil P., additional, Woody, Neil M., additional, Awan, Musaddiq, additional, Geiger, Jessica L., additional, Shreenivas, Aditya, additional, Samsa, Julia, additional, Ward, Matthew Christopher, additional, Schmitt, Nicole C., additional, Patel, Mihir R., additional, Higgins, Kristin A., additional, Teng, Yong, additional, Steuer, Conor E., additional, Shin, Dong M., additional, Liu, Yuan, additional, Ahmed, Rafi, additional, and Koyfman, Shlomo A., additional

Published
2024
Full Text
View/download PDF

24. Assessing survival outcomes of patients with oral tongue squamous cell carcinoma: Focus on age, sex, and stage.

Author

Pamulapati, Saagar, Abousaud, Marin, Li, Yixuan, Ekpenyong, Asari, Rudra, Soumon, Remick, Jill S., Bates, James E., Stokes, William A., McDonald, Mark W., Schmitt, Nicole C., El‐Deiry, Mark W., Patel, Mihir R., Steuer, Conor E., Switchenko, Jeffrey M., Shin, Dong M., Teng, Yong, Hammond, Anthea, and Saba, Nabil F.

Subjects
OVERALL survival, SQUAMOUS cell carcinoma, OLDER patients, SURVIVAL rate, DATABASES
Abstract

Background: The purpose of this study was to provide further insights into whether age and/or sex are associated with prognosis in oral tongue squamous cell carcinoma. Methods: This was a retrospective cohort study utilizing hospital registry data from 2006 to 2016 obtained from the National Cancer Database. Identified patients were divided into various cohorts based on age, sex, and staging. A descriptive analysis was performed using chi‐square tests and overall survival rates were estimated using Kaplan–Meier method. Results: A total of 17 642 patients were included in the study. The 5‐year overall survival rates were 82.0% (95% CI: 79.8%–84.0%) in younger patients versus 67.5% (95% CI: 66.7%–68.3%, p‐value <0.0001) older patients. The median overall survival for females was 143.4 months (95% CI: 133.2–NA) versus 129.8 (95% CI: 125.4–138.7, p‐value <0.0001) in males. Conclusions: Our analysis suggests that younger age and female sex are both predictors of improved survival in oral tongue squamous cell carcinoma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Do dried blood spots have the potential to support result management processes in routine sports drug testing?—Part 3: LC–MS/MS‐based peptide analysis for dried blood spot sampling time point estimation.

Author

Brockbals, Lana, Thomas, Andreas, Schneider, Tom D., Kraemer, Thomas, Steuer, Andrea E., and Thevis, Mario

Abstract

Along with the recent acknowledgement of the World Anti‐Doping Agency to use dried blood spot (DBS) samples for routine doping control purposes, there have been propositions to use DBS as a matrix that allows regular proactive remotely supervised self‐sampling, providing potential longitudinal monitoring of an athlete's exposure to doping agents. However, several organizational aspects have to be considered before implementation, such as the verification of the sample collections time point. Based on a previous untargeted proteomics workflow utilizing liquid chromatography–high‐resolution mass spectrometry (LC–HRMS) to identify protein/peptide markers to define the time since deposition of a bloodstain, the aim of the current study was to develop a targeted LC–HRMS/MS analytical method for promising peptidic target analytes. A long‐term DBS storage experiment was carried out over a 3‐month period (sample collection time points: 0, 2, 4, 7, 14, 21, 28, 42, 56, 70, 84 and 91 days) with DBS samples of 10 volunteers for longitudinal investigation of signal abundance changes of targeted peptide sequences at different storage temperatures (room temperature [RT], 4°C and −20°C). Prior to experimental analysis, LC–HRMS/MS method characteristics were successfully assessed, including intraday precision, carryover and sample extract stability. For estimation of DBS sample collection time points, ratios of two peptides that originate from the same protein prior to tryptic digestion were created. Two targeted peptide area ratios were found to significantly increase after being stored at RT for 28 days, representing potential markers for future use in routine doping controls that contribute to advancing complementary avenues in anti‐doping. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma

Author

Harvey, R. Donald, Carthon, Bradley C., Lewis, Colleen, Hossain, Mohammad S., Zhang, Chao, Chen, Zhengjia, Harris, Wayne B., Alese, Olatunji B., Shaib, Walid, Bilen, Mehmet A., Lawson, David H., Wu, Christina, Steuer, Conor E., El-Rayes, Bassel F., Khuri, Fadlo R., Lonial, Sagar, Waller, Edmund K., Ramalingam, Suresh S., and Owonikoko, Taofeek K.

Published
2020
Full Text
View/download PDF

34. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis

Author

Awad, Mark M., Leonardi, Giulia C., Kravets, Sasha, Dahlberg, Suzanne E., Drilon, Alexander, Noonan, Sinead A., Camidge, D. Ross, Ou, Sai-Hong I., Costa, Daniel B., Gadgeel, Shirish M., Steuer, Conor E., Forde, Patrick M., Zhu, Viola W., Fukuda, Yoko, Clark, Jeffrey W., Jänne, Pasi A., Mok, Tony, Sholl, Lynette M., and Heist, Rebecca S.

Published
2019
Full Text
View/download PDF

38. MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation

Author

Jin, Lingtao, Chun, Jaemoo, Pan, Chaoyun, Li, Dan, Lin, Ruiting, Alesi, Gina N., Wang, Xu, Kang, Hee-Bum, Song, Lina, Wang, Dongsheng, Zhang, Guojing, Fan, Jun, Boggon, Titus J., Zhou, Lu, Kowalski, Jeanne, Qu, Cheng-Kui, Steuer, Conor E., Chen, Georgia Z., Saba, Nabil F., Boise, Lawrence H., Owonikoko, Taofeek K., Khuri, Fadlo R., Magliocca, Kelly R., Shin, Dong M., Lonial, Sagar, and Kang, Sumin

Published
2018
Full Text
View/download PDF

40. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials

Author

Martini, Dylan J., Liu, Yuan, Shabto, Julie M., Lewis, Colleen, Kline, Meredith R., Collins, Hannah, Akce, Mehmet, Kissick, Haydn T., Carthon, Bradley C., Shaib, Walid L., Alese, Olatunji B., Pillai, Rathi N., Steuer, Conor E., Wu, Christina S., Lawson, David H., Kudchadkar, Ragini R., Master, Viraj A., El-Rayes, Bassel F., Ramalingam, Suresh S., Owonikoko, Taofeek K., Harvey, R. Donald, and Bilen, Mehmet Asim

Published
2019
Full Text
View/download PDF

42. New gamma‐hydroxybutyric acid (GHB) biomarkers: Development and validation of a liquid chromatography–tandem mass spectrometry method for the determination of GHB amino acid, carnitine, and fatty acid conjugates in urine

Author

Steuer, Andrea E, Sutter, Linda, Steuer, Christian, Kraemer, Thomas, and University of Zurich

Subjects
340 Law, Pharmaceutical Science, Environmental Chemistry, 610 Medicine & health, 10218 Institute of Legal Medicine, Spectroscopy, Analytical Chemistry
Abstract

Gamma-hydroxybutyric acid (GHB) represents an important drug in clinical and forensic toxicology, particularly in the context of drug-facilitated crimes. Analytically, GHB remains a major challenge given its endogenous occurrence and short detection window. Previous studies identified a number of potential interesting novel conjugates of GHB with carnitine, amino acids (AA, glutamate, glycine, and taurine) or fatty acids. As a basis for comprehensive studies on the suitability of these novel biomarkers, we developed and validated a liquid chromatography - tandem mass spectrometry (LC-MS/MS) method in human urine. Additionally, already knowns markers 2,4-dihydroxy butyric acid (2,4-DHB), 3,4-DHB, glycolic acid, succinic acid, succinylcarnitine, and GHB glucuronide were included. The method was fully validated according to (inter)national guidelines. Synthetic urine proved suitable as a surrogate matrix for calibration. Matrix effects were observed for all analytes with suppression effects of about 50% at QC LOW, and approximately 20 to 40% at QC HIGH, but with consistent standard deviation of25% at QC LOW and15% at QC HIGH, respectively. All analytes showed acceptable intra- and inter-day imprecision of below 20%, except for inter-day variation of GHB taurine and FA conjugates at the lowest QC. Preliminary applicability studies proved the usefulness of the method and pointed towards GHB glycine, followed by other AA conjugates as the most promising candidates to improve GHB detection. FA conjugates were not detected in urine samples yet. The method can be used now for comprehensive sample analysis on (controlled) GHB administration to prove the usefulness of the novel GHB biomarkers.

Published
2023
Full Text
View/download PDF

44. The evolving landscape of salivary gland tumors

Author

Steuer, Conor E., primary, Hanna, Glenn J., additional, Viswanathan, Kartik, additional, Bates, James E., additional, Kaka, Azeem S., additional, Schmitt, Nicole C., additional, Ho, Alan L., additional, and Saba, Nabil F., additional

Published
2023
Full Text
View/download PDF

45. Multicriteria Decision Aid/Analysis in Finance

Author

Spronk, Jaap, Steuer, Ralph E., Zopounidis, Constantin, Price, Camille C., Series editor, Zhu, Joe, Series editor, Hillier, Frederick S., Series editor, Greco, Salvatore, editor, Ehrgott, Matthias, editor, and Figueira, José Rui, editor

Published
2016
Full Text
View/download PDF

49. Chronic 3,4-Methylenedioxymethamphetamine (MDMA) use is related to glutamate and GABA concentrations in the striatum, but not in the anterior cingulate cortex

Author

Zimmermann, Josua, primary, Zölch, Niklaus, additional, Coray, Rebecca, additional, Bavato, Francesco, additional, Friedli, Nicole, additional, Baumgartner, Markus R, additional, Steuer, Andrea E, additional, Opitz, Antje, additional, Werner, Annett, additional, Oeltzschner, Georg, additional, Seifritz, Erich, additional, Stock, Ann Kathrin, additional, Beste, Christian, additional, Cole, David M, additional, and Quednow, Boris B, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results